Hyper Lab Blog

Did you know that molecular docking, a key tool in drug discovery, can yield vastly different results depending on how you configure settings like thoroughness, scoring functions, and flexible residues?

Ultra-large compound libraries leverage DEL technology and AI to increase the efficiency of drug discovery, expanding chemical diversity and the potential for hit discovery.

Sunghan Bae from the HITS AI research team won the 2nd AI Drug Discovery Competition, utilizing the MolClr model and HyperLab's binding affinity predictions to overcome data shortages and imbalances.

Seladelpar, a treatment for Primary Biliary Cholangitis, has received FDA accelerated approval. This rare autoimmune disease, mainly affecting middle-aged women, is now addressed by seladelpar’s high selectivity and fewer side effects.

We describe the clinical development status and characteristics of seven new drugs first presented at EFMC-ISMC in 2024.

We interviewed Ryan Kern from the Georgia Institute of technology about the Hyper Lab, and how it integrates experimentation and computation, and has proven to be very useful in optimizing drug candidates.

EFMC-ISMC 2024 is an international pharmacology symposium taking place September 1-5 in Rome, Italy, and is divided into three main sessions. HITS will be introducing Hyper Lab, an AI drug discovery platform.

It's been a decade since AI entered the drug discovery race, but where are we in the pipeline of drugs discovered by AI-powered drug discovery platforms? In this post, we'll summarize the targets and trends in their development.

We interviewed Celine Evbuomwan and Caitlyn Santos, pharmacy students at Midwestern University, about the Hyper Lab. Their positive feedback was that the Hyper Lab is easy to use and well-stocked with tutorials.

In this Hyper Lab interview, José Antonio Costoya, Head of the Molecular Oncology Laboratory at the University of Santiago de Compostela CiMUS, talks about his research and the AI drug discovery platform Hyper Lab.